Loading...
XNAS
SHPH
Market cap3mUSD
Jun 16, Last price  
3.26USD
1D
-1.81%
1Q
676.19%
IPO
-93.78%
Name

Shuttle Pharmaceuticals Holdings Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
-26.64%
Rev. gr., 5y
%
Revenues
0k
Net income
-9.14b
L+138,610.47%
-213,594-626,139-845,362-1,202,922-3,099,457-6,592,723-9,144,797,000
CFO
-7.33b
L+131,185.38%
-202,705-566,692-26,831-300,336-2,710,454-5,581,147-7,327,230,000

Profile

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
IPO date
Aug 31, 2022
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122018‑122017‑12
Income
Revenues
Cost of revenue
5,011,505
4,571
2,621
Unusual Expense (Income)
NOPBT
(5,011,505)
(4,571)
(2,621)
NOPBT Margin
Operating Taxes
71
Tax Rate
NOPAT
(5,011,505)
(4,571)
(2,692)
Net income
(9,144,797)
138,610.47%
(6,593)
112.71%
(3,099)
157.66%
Dividends
(402)
Dividend yield
1.98%
Proceeds from repurchase of equity
3,993
2,698
10,022
BB yield
-160.98%
-37.28%
-49.40%
Debt
Debt current
1,413,565
701
748
Long-term debt
238,625
796
63
Deferred revenue
Other long-term liabilities
25,043
415
865
Net debt
(267,954)
(3,967)
(7,606)
Cash flow
Cash from operating activities
(7,327,230)
(5,581)
(2,710)
CAPEX
(19)
Cash from investing activities
2,915,765
(2,830)
Cash from financing activities
3,755,193
2,570
10,623
FCF
(5,182,011)
(4,861)
(3,421)
Balance
Cash
1,920,144
5,464
8,417
Long term investments
Excess cash
1,920,144
5,464
8,417
Stockholders' equity
(34,578,101)
(25,433)
(8,895)
Invested Capital
36,964,187
31,044
17,321
ROIC
ROCE
EV
Common stock shares outstanding
2,887
15,907
10,351
Price
0.86
88.79%
0.46
-76.79%
1.96
 
Market cap
2,480
-65.73%
7,238
-64.33%
20,288
 
EV
(265,474)
3,271
12,682
EBITDA
(5,006,042)
(4,564)
(2,554)
EV/EBITDA
0.05
Interest
8,692
2,595
970
Interest/NOPBT